The manufacture of finished doses will commence in 2022 and at full operational capacity, the annual production is expected to exceed 100 million doses annually
The co-investment of CHF 4 million will result in capacity expansion and support the market introduction of the customer's lead compound
The Endosonography allows the use of EUS guided Fine needle aspiration for accurate diagnosis of GI cancers without the need for conventional biopsies
_256_384.jpg)
It has initiated investments for advanced medical equipment such as Cath Labs, neuro microscopes, bone marrow transplant units at select facilities
_256_384.jpg)
The antiviral technology involves the presence of active positive charges on the fabric, as binding sites for viruses and on contact with the fabric, virus cells that are negatively charged are neutralised, leading to the rapid destruction of their glycoprotein layers and the release of non-infectious ribonucleic acid (RNA)
Winlevi, the recently added anti-acne product with a new mechanism of action and broad-based use (vs Absorica), will further boost the derma portfolio and Speciality business growth
Demand normalisation post the second wave contributed to the steady growth
Company working on COVID vaccine INO 4800
Proceeds from the IPO will be used for the expansion of the Dehradun facility.
The expanded laboratories and manufacturing facilities at Nansha are expected to come online between Q1 2022 and Q3 2022
Subscribe To Our Newsletter & Stay Updated
